81 related articles for article (PubMed ID: 18054088)
1. Published studies reporting the efficacy of soluble CD83 in vitro as well as in vivo.
Zinser E; Steinkasserer A
Immunol Lett; 2008 Jan; 115(1):18-9. PubMed ID: 18054088
[No Abstract] [Full Text] [Related]
2. Therapeutic activity of soluble CD83: comments on Pashine et al.
Chou CP
Immunol Lett; 2008 Jan; 115(1):20. PubMed ID: 18093663
[No Abstract] [Full Text] [Related]
3. Failed efficacy of soluble human CD83-Ig in allogeneic mixed lymphocyte reactions and experimental autoimmune encephalomyelitis: implications for a lack of therapeutic potential.
Pashine A; Göpfert U; Chen J; Hoffmann E; Dietrich PS; Peng SL
Immunol Lett; 2008 Jan; 115(1):9-15. PubMed ID: 18079004
[TBL] [Abstract][Full Text] [Related]
4. CD83: a regulatory molecule of the immune system with great potential for therapeutic application.
Fujimoto Y; Tedder TF
J Med Dent Sci; 2006 Jun; 53(2):85-91. PubMed ID: 16913569
[TBL] [Abstract][Full Text] [Related]
5. CD83: regulator of central T cell maturation and peripheral immune response.
Breloer M
Immunol Lett; 2008 Jan; 115(1):16-7. PubMed ID: 18022250
[No Abstract] [Full Text] [Related]
6. Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia.
Hock BD; Fernyhough LJ; Gough SM; Steinkasserer A; Cox AG; McKenzie JL
Leuk Res; 2009 Aug; 33(8):1089-95. PubMed ID: 19195701
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell CD83: a therapeutic target or innocent bystander?
Prazma CM; Tedder TF
Immunol Lett; 2008 Jan; 115(1):1-8. PubMed ID: 18001846
[TBL] [Abstract][Full Text] [Related]
8. Local secretion/shedding of tumor-derived CD83 molecules as a novel tumor escape mechanism.
Baleeiro RB; Barbuto JA
Mol Immunol; 2008 Jul; 45(12):3502-4. PubMed ID: 18513799
[TBL] [Abstract][Full Text] [Related]
9. Engagement of CD83 on B cells modulates B cell function in vivo.
Kretschmer B; Lüthje K; Schneider S; Fleischer B; Breloer M
J Immunol; 2009 Mar; 182(5):2827-34. PubMed ID: 19234177
[TBL] [Abstract][Full Text] [Related]
10. CD83 regulates lymphocyte maturation, activation and homeostasis.
Breloer M; Fleischer B
Trends Immunol; 2008 Apr; 29(4):186-94. PubMed ID: 18329338
[TBL] [Abstract][Full Text] [Related]
11. CD83 on murine APC does not function as a costimulatory receptor for T cells.
Kretschmer B; Lüthje K; Ehrlich S; Osterloh A; Piedavent M; Fleischer B; Breloer M
Immunol Lett; 2008 Oct; 120(1-2):87-95. PubMed ID: 18675848
[TBL] [Abstract][Full Text] [Related]
12. CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.
Li Z; Ju X; Lee K; Clarke C; Hsu JL; Abadir E; Bryant CE; Pears S; Sunderland N; Heffernan S; Hennessy A; Lo TH; Pietersz GA; Kupresanin F; Fromm PD; Silveira PA; Tsonis C; Cooper WA; Cunningham I; Brown C; Clark GJ; Hart DNJ
Haematologica; 2018 Apr; 103(4):655-665. PubMed ID: 29351987
[TBL] [Abstract][Full Text] [Related]
13. CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.
Li Z; Ju X; Silveira PA; Abadir E; Hsu WH; Hart DNJ; Clark GJ
Front Immunol; 2019; 10():1312. PubMed ID: 31231400
[TBL] [Abstract][Full Text] [Related]
14. Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression.
Jin O; Kavikondala S; Sun L; Fu R; Mok MY; Chan A; Yeung J; Lau CS
Lupus; 2008 Jul; 17(7):654-62. PubMed ID: 18625638
[TBL] [Abstract][Full Text] [Related]
15. CD83 regulates splenic B cell maturation and peripheral B cell homeostasis.
Lüthje K; Kretschmer B; Fleischer B; Breloer M
Int Immunol; 2008 Aug; 20(8):949-60. PubMed ID: 18544574
[TBL] [Abstract][Full Text] [Related]
16. Direct contact of platelets and their released products exert different effects on human dendritic cell maturation.
Hamzeh-Cognasse H; Cognasse F; Palle S; Chavarin P; Olivier T; Delézay O; Pozzetto B; Garraud O
BMC Immunol; 2008 Sep; 9():54. PubMed ID: 18817542
[TBL] [Abstract][Full Text] [Related]
17. A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling.
Ju S; Ju S; Ge Y; Qiu H; Lu B; Qiu Y; Fu J; Liu G; Wang Q; Hu Y; Shu Y; Zhang X
Int Immunol; 2009 Oct; 21(10):1135-44. PubMed ID: 19684160
[TBL] [Abstract][Full Text] [Related]
18. A highly phagocytic cell line TO from Atlantic salmon is CD83 positive and M-CSFR negative, indicating a dendritic-like cell type.
Pettersen EF; Ingerslev HC; Stavang V; Egenberg M; Wergeland HI
Fish Shellfish Immunol; 2008 Dec; 25(6):809-19. PubMed ID: 18817880
[TBL] [Abstract][Full Text] [Related]
19. Bioprocess development for production, purification, and structural characterization of recombinant hCD83ext as a potential therapeutic protein.
Xu Y; Zhang L; Yao W; Yedahalli SS; Brand S; Moo-Young M; Perry Chou C
Protein Expr Purif; 2009 May; 65(1):92-9. PubMed ID: 19116168
[TBL] [Abstract][Full Text] [Related]
20. Multicenter study on in vitro characterization of dendritic cells.
Eichler H; Nguyen XD; Roelen D; Celluzzi CM; McKenna D; Pamphilon D; Blair A; Read EJ; Takahashi TA; Szczepiorkowski ZM;
Cytotherapy; 2008; 10(1):21-9. PubMed ID: 18202971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
